White House's removal of AstraZeneca COVID-19 shot production from Emergent plant won't affect its dose output - official
- Country:
- United States
The U.S. government's removal of AstraZeneca PLC's COVID-19 shot production from Emergent BioSolutions Inc's Baltimore manufacturing facility does not suggest it has any concerns about the vaccine's safety or effectiveness and will not impact its output of doses, a White House official said on Monday. The U.S. Department of Health and Human Services ordered Johnson & Johnson to take charge of production at Emergent and for Emergent to stop making AstraZeneca's shots after the contract manufacturer made an error that ruined 15 million J&J COVID-19 vaccine doses.
"This is a decision that HHS made with Johnson & Johnson and AstraZeneca in complete collaboration," White House COVID-19 adviser Andy Slavitt told reporters during a press conference.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
- READ MORE ON:
- Andy Slavitt
- White House
- Johnson & Johnson
- U.S.
- Baltimore
- AstraZeneca
ALSO READ
Muslim community members in US decline White House Iftar dinner invite: media reports
Science News Roundup: White House directs NASA to create time standard for the moon; Wide swath of US will get buggy as two cicada broods intrude and more
Science News Roundup: White House directs NASA to create time standard for the moon; Gene involved in cell shape offers clues on left-handedness
Centrist group No Labels drops third-party White House bid
Centrist group No Labels drops third-party White House bid